Abstract Body

Background: HIV-infected individuals (“controllers”) who are able to maintain low levels of plasma RNA in the absence of antiretroviral therapy (ART) have stable low-level viremia, elevated T cell activation, and a higher risk of cardiovascular disease (CVD). The mechanisms underlying this increased risk are unknown but may include low-level viral replication leading to chronic inflammation and subsequent endothelial dysfunction. Methodology: We performed an open-label study to compare the impact of ART on endothelial function (as measured by flow-mediated vasodilation of the brachial artery [FMD]) and microvascular function (as measured by hyperemic velocity [HV]) in “elite” controllers (EC, n=4), viremic controllers (VC, n=11), and non-controllers (NC, n=5). Lower levels of FMD and HV have been shown to be predictors of future CVD. All subjects received 24-36 weeks of RGV+TDF/FTC. FMD and HV were measured at weeks 0, 4, 24, and 36. Linear mixed models were used to evaluate changes in FMD and HV. Results: Baseline FMD levels were 6.9}2.0% (EC), 5.3}0.9 (VC), and 6.3}1.7% (NC) (p=0.18, overall test of difference). There were no statistically significant changes over time in FMD (p=0.24), and FMD did not differ significantly between groups (EC vs. NC, p=0.98; VC vs. NC, p=0.17). Baseline HV levels were 101.5}31cm (EC), 89.8}19.7cm (VC), and 67.3}24.2cm (NC) (p=0.14, overall test of difference). Overall, HV was 39.9 cm higher in EC vs. NC (p=0.018) and somewhat higher in VC vs. NC (+20.0cm, p=0.13). Both proviral DNA and %CD8+PD1+ levels were significantly lower in EC patients compared to NC at weeks 0, 4, 24; models which controlled for these factors attenuated the differences in HV between EC and NC. Conclusions: In this small pilot study, while 24 weeks of ART resulted in significant reductions in levels of ultrasensitive plasma RNA and T cell activation in HIV-infected controllers, this did not translate into improved macrovascular function (as measured by FMD). However, controllers as a group had better microvascular function (as measured by HV) compared to non-controllers; lower proviral DNA levels and lower markers of immune dysfunction in controllers appeared to mediate the differences in HV. Thus, HIV persistence and immune dysfunction may preferentially impact the microvasculature (rather than the macrovasculature), which may contribute to increased CVD risk. These findings should be replicated in future larger studies that also account for differences between the groups in traditional CVD risk factors.